Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SGIOF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SGIOF and 80,000+ other tickers.
See exactly how SGIOF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SGIOF and 80,000+ other tickers.
Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral medication targeting influenza; and Tivicay, which is used in HIV management. Shionogi actively pursues the development of numerous compounds addressing a wide array of medical conditions. Its investigational pipeline features…
Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has been awarded a contract through the Biomedical Advanced Research and Development Authority's (BARDA) Project BioShield related to Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens that prese.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team memb.
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Esprit, a global Phase 2 clinical trial evaluating S-606001, an investigational drug for the treatment of late-onset Pompe disease (LOPD). Esprit is a multicenter, randomized, placebo-controlled, double-blind study evaluating the safety, pharmacodynamics and preliminary efficacy of S-606001 as an o.